S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
Log in

NASDAQ:NTGN - Neon Therapeutics Stock Price, Forecast & News

$1.57
-0.09 (-5.42 %)
(As of 01/27/2020 04:00 PM ET)
Today's Range
$1.56
Now: $1.57
$1.64
50-Day Range
$1.00
MA: $1.26
$1.82
52-Week Range
$0.88
Now: $1.57
$7.51
Volume436,429 shs
Average Volume664,896 shs
Market Capitalization$44.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTGN
CUSIPN/A
CIKN/A
Phone617-337-4701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.58 per share

Profitability

Net Income$-76,930,000.00

Miscellaneous

Employees102
Market Cap$44.49 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive NTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter.


Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions

What is Neon Therapeutics' stock symbol?

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) issued its earnings results on Tuesday, November, 12th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.04. View Neon Therapeutics' Earnings History.

When is Neon Therapeutics' next earnings date?

Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neon Therapeutics.

What price target have analysts set for NTGN?

6 brokers have issued 1-year price targets for Neon Therapeutics' shares. Their forecasts range from $2.18 to $15.00. On average, they anticipate Neon Therapeutics' share price to reach $10.24 in the next year. This suggests a possible upside of 552.0% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.

What is the consensus analysts' recommendation for Neon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neon Therapeutics.

What are Wall Street analysts saying about Neon Therapeutics stock?

Here are some recent quotes from research analysts about Neon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company's product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. " (1/4/2020)
  • 2. HC Wainwright analysts commented, "Our assessment is driven by a discounted cash flow (DCF)-based approach, which utilizes a 10% discount rate, 1.0% terminal growth rate, and 30% probability of approval for NEO-PV-01 in front-line melanoma, NSCLC, and bladder cancer. We assume a 29% effective tax rate." (9/16/2019)

Has Neon Therapeutics been receiving favorable news coverage?

News coverage about NTGN stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neon Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Neon Therapeutics.

Are investors shorting Neon Therapeutics?

Neon Therapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totalling 573,900 shares, a decrease of 19.6% from the December 31st total of 713,900 shares. Based on an average daily trading volume, of 204,200 shares, the short-interest ratio is presently 2.8 days. Approximately 4.0% of the company's shares are sold short. View Neon Therapeutics' Current Options Chain.

Who are some of Neon Therapeutics' key competitors?

What other stocks do shareholders of Neon Therapeutics own?

Who are Neon Therapeutics' key executives?

Neon Therapeutics' management team includes the folowing people:
  • Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
  • Dr. Eric S. Lander, Founder & Director (Age 62)
  • Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
  • Dr. Richard Gaynor, Pres of R&D (Age 69)
  • Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer

When did Neon Therapeutics IPO?

(NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Neon Therapeutics' major shareholders?

Neon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.88%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View Institutional Ownership Trends for Neon Therapeutics.

Which institutional investors are buying Neon Therapeutics stock?

NTGN stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Neon Therapeutics.

How do I buy shares of Neon Therapeutics?

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neon Therapeutics' stock price today?

One share of NTGN stock can currently be purchased for approximately $1.57.

How big of a company is Neon Therapeutics?

Neon Therapeutics has a market capitalization of $44.49 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics.

What is Neon Therapeutics' official website?

The official website for Neon Therapeutics is http://www.neontherapeutics.com/.

How can I contact Neon Therapeutics?

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]


MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel